Last reviewed · How we verify
Paclitaxel and Carboplatin or Ifosfamide in Treating Patients With Newly Diagnosed, Persistent or Recurrent Uterine, Ovarian, Fallopian Tube, or Peritoneal Cavity Cancer
This randomized phase III trial studies paclitaxel and carboplatin see how well they work compared with paclitaxel and ifosfamide in treating patients with fallopian tube, or peritoneal cavity cancer that is newly diagnosed, persistent, or has come back (recurrent). Drugs used in chemotherapy, such as paclitaxel, carboplatin, and ifosfamide, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. It is not yet known whether paclitaxel is more effective when given with carboplatin or ifosfamide in treating patients with uterine, ovarian, fallopian tube, or peritoneal cavity cancer.
Details
| Lead sponsor | GOG Foundation |
|---|---|
| Phase | PHASE3 |
| Status | UNKNOWN |
| Enrolment | 637 |
| Start date | Mon Aug 17 2009 00:00:00 GMT+0000 (Coordinated Universal Time) |
Conditions
- Mixed Mesodermal (Mullerian) Tumor
- Ovarian Carcinosarcoma
- Recurrent Fallopian Tube Carcinoma
- Recurrent Ovarian Carcinoma
- Recurrent Primary Peritoneal Carcinoma
- Stage I Ovarian Cancer AJCC v6 and v7
- Stage IA Fallopian Tube Cancer AJCC v6 and v7
- Stage IA Ovarian Cancer AJCC v6 and v7
- Stage IA Uterine Sarcoma AJCC v7
- Stage IB Fallopian Tube Cancer AJCC v6 and v7
Interventions
- Carboplatin
- Ifosfamide
- Paclitaxel
- Quality-of-Life Assessment
Countries
United States, South Korea